AR-12286 ophthalmic solution (0.5% and 0.7%)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AR-12286 ophthalmic solution (0.5% and 0.7%), covering 2015-04-24 to 2015-04-24. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt [Phase 2]